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Science, South Carolina College of Pharmacy, University of South Carolina and 3) Department of Clinical Pharmacy, Palmetto Health Richland, Columbia, SC, USAAbstractThere has been a concerning increase in ﬂuoroquinolone resistance among Gram-negative bloodstream isolates. This retrospective cohort
study examines the implications of ﬂuoroquinolone resistance on use of healthcare resources in patients with Gram-negative bloodstream
infections (BSI). Hospitalized adults with ﬁrst episodes of community-onset Gram-negative BSI from 2010 to 2012 at Palmetto Health
Hospitals in Columbia, SC, USA were identiﬁed. Multivariate linear regression was used to examine risk factors for prolonged hospital
length of stay (HLOS) in survivors of Gram-negative BSI. Among 474 unique patients, 384 (81%) and 90 (19%) had BSI due to
ﬂuoroquinolone-susceptible (FQ-S) and ﬂuoroquinolone non-susceptible (FQ-NS) Gram-negative bacilli, respectively. The FQ-NS
bloodstream isolates, particularly Escherichia coli, were more likely than FQ-S isolates to be multi-drug resistant (56% versus 6%,
p < 0.001). Compared with patients with BSI due to FQ-S bloodstream isolates, those with FQ-NS isolates were more likely to receive
inappropriate empirical antimicrobial therapy (26% versus 3%, p < 0.001), have longer mean HLOS (11.6 versus 9.3 days, p 0.03) and
treatment duration with intravenous antibiotics during hospitalization (9.1 versus 7.1 days, p 0.001), and use outpatient intravenous
antibiotics at hospital discharge (15% versus 8%, p 0.05). After adjustments in the multivariate model, inappropriate empirical
antimicrobial therapy was an independent risk factor for prolonged HLOS in survivors of Gram-negative BSI (parameter estimate 3.65
days, 95% CI 0.43–6.86). Multi-drug resistance among FQ-NS bloodstream isolates limits both empirical and deﬁnitive antimicrobial
treatment options and poses excessive burdens on the healthcare system.
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E-mail: majdi.alhasan@uscmed.sc.eduIntroductionBloodstream infections (BSI) make a major contribution to the
morbidity and mortality of the general population in North
America and Europe [1–4]. The survival beneﬁt from appro-
priate antimicrobial therapy for BSI has emphasized theClinical Microbiology and Infection © 2015 European Society of Cimportance of optimizing both empirical and deﬁnitive treat-
ment regimens [5–7]. Due to relatively high bioavailability of
ﬂuoroquinolones, this class of antimicrobial agents has been
popular for intravenous to oral switch therapy in hospitalized
patients with serious Gram-negative infections, including BSI.
However, recent increase in antimicrobial resistance rates of
ﬂuoroquinolones among Escherichia coli and other Gram-
negative bloodstream isolates has limited antimicrobial treat-
ment options [8–10]. In addition, the association between
resistance to ﬂuoroquinolones and other antimicrobial agents
such as trimethoprim-sulfamethoxazole and amoxicillin-
clavulanate has left many patients without reliable oral antimi-
crobial options for deﬁnitive outpatient therapy [8,10]. ThisClin Microbiol Infect 2015; 21: 843–849
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.05.013
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more patients may stay longer in the hospital to receive inpa-
tient intravenous antimicrobial therapy or to allow arrange-
ments for outpatient intravenous antibiotics.
In this retrospective cohort study, we examined the impact
of ﬂuoroquinolone non-susceptibility (FQ-NS) in patients with
community-onset Gram-negative BSI on hospital length of stay
(HLOS) and need for outpatient intravenous antibiotics upon
hospital discharge.Materials and methodsSetting
The Palmetto Health System in Columbia, SC, USA, includes
Palmetto Health Richland Hospital and Palmetto Health Baptist
Hospital with a combined bed capacity of >1100 licensed beds.
Both hospitals provide care for local residents of Richland
County as well as for regional referrals from within the State of
South Carolina, in a wide variety of medical and surgical
subspecialties.
Deﬁnitions
Gram-negative BSI was deﬁned as the growth of any aerobic
Gram-negative bacillus in a blood culture. The primary source
of infection was identiﬁed according to the Centers for Disease
Control and Prevention criteria [11]. The site of infection
acquisition was divided into community-onset and hospital-
acquired. Community-onset BSI was further divided into
community-acquired or healthcare-associated as deﬁned by
Friedman [12]. FQ-NS isolates were deﬁned as Gram-negative
bacilli that were not susceptible in vitro to ciproﬂoxacin ac-
cording to the CLSI with MIC 2. Gram-negative bacilli were
considered multi-drug resistant if they were non-susceptible to
three or more classes of antibiotics [13]. Empirical antimicro-
bial therapy was deﬁned as antimicrobial agents received within
the ﬁrst 48 h following collection of the ﬁrst set of positive
blood cultures. Appropriate empirical antimicrobial therapy
was deﬁned as receipt of an empirical antimicrobial agent with
appropriate route and dosage and in vitro activity against Gram-
negative bloodstream isolates using CLSI guidelines as previ-
ously deﬁned [5,6].
Case ascertainment
All patients with BSI due to aerobic Gram-negative bacilli from
1 January 2010 to 31 December 2012 were identiﬁed through
the Palmetto Health microbiology laboratory database. Hospi-
talized adults with ﬁrst episodes of community-onset Gram-
negative BSI were included in the study (n = 474). Children <18
years old (n = 98), recurrent BSI (n = 34), polymicrobial BSIClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(n = 121) and patients treated in outpatient settings (n = 29)
were excluded. Patients with hospital-acquired BSI (n = 126)
were also excluded as HLOS may be dictated by the primary
hospital admission diagnosis rather than BSI.
Statistical analysis
Linear regression was used to examine the primary outcome of
the study, which is the association between FQ-NS and HLOS
in hospitalized patients who survived Gram-negative BSI. The
analysis was limited to survivors to avoid accounting for early
death as a favourable outcome. Potential co-variates associated
with HLOS were examined using univariate linear regression.
To identify factors that were independently associated with
HLOS, variables were included in a multivariate linear regres-
sion model if the p value for a univariate association with HLOS
was 0.10. In addition, differences between ﬂuoroquinolone-
susceptible (FQ-S) and FQ-NS bloodstream isolates were
identiﬁed. Chi-squared or Fisher’s exact test, as appropriate,
was used to examine for associations between categorical
variables and ﬂuoroquinolone susceptibility, and Student’s t test
was used to assess for differences in continuous variables.
Factors with a p value 0.10 were also included as covariates in
the ﬁnal linear regression model. Parameter estimates with 95%
CI were presented to demonstrate the strength of association
between each risk factor and HLOS.
Kaplan–Meier survival analysis was used to compare 28-day
mortality in patients with BSI due to FQ-S and FQ-NS Gram-
negative bacilli to allow the censoring of patients who were lost
to follow up within 28 days of BSI. Log-rank test was used to
calculate the p value for a difference in mortality between the
two groups. The association between FQ-NS and need for
outpatient intravenous antibiotics at hospital discharge was
examined using Chi-squared or Fisher’s exact test, as appro-
priate. In a post-hoc analysis, multivariate logistic regression
was used to examine risk factors for receiving inappropriate
empirical antimicrobial therapy. Odds ratios with 95% CI were
reported to demonstrate the association between each variable
and inappropriate therapy.
JMP (version 10.0, SAS Institute Inc, Cary, NC, USA) was
used for statistical analysis. The level of signiﬁcance for statis-
tical testing was deﬁned as p < 0.05 (two-sided) unless other-
wise speciﬁed.ResultsAmong 474 patients with community-onset Gram-negative BSI
during the 3-year study period, 384 (81%) had BSI due to FQ-S
and 90 (19%) had BSI due to FQ-NS isolates. The baseline
clinical characteristics of patients are shown in Table 1.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 843–849
TABLE 1. Demographic and clinical characteristics of patients with Gram-negative bloodstream infections
Variable FQ-S (n [ 384) FQ-NS (n [ 90) p
Age in years, mean ± SD 64 ± 18 67 ± 16 0.15
Gender, n (%) 0.004
Female 243 (63) 42 (47)
Male 141 (37) 48 (53)
Ethnicity, n (%) 0.94
White 188 (49) 45 (50)
African-American 185 (48) 43 (48)
Other 11 (3) 2 (2)
Diabetes mellitus, n (%) 136 (35) 36 (40) 0.42
End-stage renal disease, n (%) 34 (9) 8 (9) 0.99
Liver cirrhosis, n (%) 7 (2) 3 (3) 0.41
Cancer, n (%) 61 (16) 16 (18) 0.66
Immune compromised host, n (%) 64 (17) 10 (11) 0.19
Site of infection acquisition, n (%) 0.05
Community-acquired 210 (55) 39 (43)
Healthcare-associated 174 (45) 51 (57)
Pitt bacteraemia score, n (%) 0.03
<4 305 (79) 62 (69)
4 79 (21) 28 (31)
Source of infection, n (%) 0.94
Urinary 232 (60) 54 (60)
Non-urinary 152 (40) 36 (40)
Inappropriate empirical antimicrobial therapy, n (%) 12 (3) 23 (26) <0.001
Hospital length of stay in days,a mean ± SD 9.3 ± 7.7 11.6 ± 10.2 0.03
Duration of inpatient intravenous antibiotics in days,a mean ± SD 7.1 ± 4.5 9.1 ± 5.6 0.001
Hospital discharge on intravenous antibiotics,a n/N (%) 26/337 (8) 11/74 (15) 0.05
Hospital discharge on oral antibiotics,a n/N (%) 189/337 (56) 22/74 (30) <0.001
Note: FQ-S, ﬂuoroquinolone-susceptible; FQ-NS, ﬂuoroquinolone non-susceptible; SD, standard deviation.
aAmong patients who survived hospitalization.
CMI Brigmon et al. Fluoroquinolone-resistant bloodstream isolates 845Compared with patients with BSI due to FQ-S organisms, those
with BSI due to FQ-NS isolates were more likely to be men, to
have healthcare-associated acquisition and higher Pitt bacter-
aemia scores, and to receive inappropriate empirical antimi-
crobial therapy.
Overall, E. coli was the most common bloodstream isolate
(270; 57%) followed by Klebsiella species (82; 17%), Proteus
mirabilis (40; 8%) and Pseudomonas aeruginosa (24; 5%). Patients
with BSI due to FQ-NS isolates were more likely than those
with FQ-S organisms to have E. coli BSI (78% versus 52%, p
0.03). In vitro antimicrobial susceptibility testing results of E. coli
bloodstream isolates are listed in Table 2. FQ-NS E. coli were
more likely than FQ-S E. coli bloodstream isolates to be resis-
tant to most tested antibiotics, produce extended-spectrumTABLE 2. In vitro antimicrobial susceptibility of Escherichia coli
bloodstream isolates, 2010–2012
Antibiotic FQ-S (n [ 200) FQ-NS (n [ 70) p
Ampicillin 108 (54) 7 (10) <0.001
Amoxicillin-clavulanate 158 (79) 34 (49) <0.001
Cefazolin 179 (90) 51 (73) <0.001
Ceftriaxone 195 (98) 58 (83) <0.001
Ceftazidime 195/199 (98) 59/69 (86) <0.001
Cefepime 196 (98) 62 (89) 0.002
Ertapenem 200 (100) 70 (100) 0.99
Gentamicin 189 (95) 54 (77) <0.001
Piperacillin-tazobactam 197/198 (99) 62/69 (90) <0.001
Tetracycline 93/117 (80) 18/41 (44) <0.001
Trimepthoprim-sulfamethoxazole 160/199 (80) 35 (50) <0.001
Note: FQ-S, ﬂuoroquinolone-susceptible; FQ-NS, ﬂuoroquinolone non-susceptible.
Data show number of susceptible isolates (percentage of susceptible isolates) if all
isolates were tested; otherwise number of susceptible isolates/number of isolates
tested (percentage of susceptible isolates).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyβ-lactamases (11% versus 2%, p 0.003), and be multi-drug
resistant (56% versus 6%, p < 0.001).
FQ-NS was independently associated with receiving inap-
propriate empirical antimicrobial therapy (OR 11.02; 95% CI
5.28–24.17, p < 0.001) after adjustments for other variables in
multivariate logistic regression model (see Supplementary ma-
terial, Table S1). Inappropriate empirical antimicrobial therapy
in patients with FQ-NS bloodstream isolates was not solely
driven by empirical use of ﬂuoroquinolones. Among 23 patients
with BSI due to FQ-NS Gram-negative bacilli who received
inappropriate antimicrobial therapy, 7 (30%) received empirical
ﬂuoroquinolones, 6 (26%) received β-lactams, 4 (17%) received
β-lactam/ﬂuoroquinolone combinations, 2 (9%) received ami-
noglycosides, 1 (4%) received β-lactam/aminoglycoside combi-
nations, and the remaining 3 (13%) received either delayed or
other antibiotic regimens.
In Kaplan–Meier survival analysis, 28-day all-cause mortality
was 19% (95% CI 11–27%) and 12% (95% CI 9–16%) in pa-
tients with BSI due to FQ-NS and FQ-S Gram-negative bacilli,
respectively (p 0.10). Among survivors of BSI, the mean dura-
tion of hospitalization was nearly 2 days longer in patients with
BSI due to FQ-NS organisms compared with those with BSI due
to FQ-S isolates (11.6 versus 9.3 days, p 0.03). In a univariate
linear regression model, male gender, non-urinary source of
infection, higher Pitt bacteraemia score, receipt of inappro-
priate empirical antimicrobial therapy and FQ-NS were asso-
ciated with longer HLOS (Table 3). However, after adjustments
in the multivariate linear regression model, non-urinary source
of infection, higher Pitt bacteraemia score and inappropriateand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 843–849
TABLE 3. Univariate linear regression results for risk factors
of prolonged hospital length of stay in survivors of Gram-
negative bloodstream infection
Variable
Parameter
estimate
in days 95% CI p
Age (per decade) 0.36 –0.09 to 0.80 0.12
Male gender 2.02 0.38–3.66 0.02
White ethnicity –1.33 –2.93 to 0.27 0.10
Non-urinary source of infection 2.83 1.19–4.47 <0.001
Diabetes mellitus 1.13 –0.51 to 2.78 0.18
End-stage renal disease 1.17 –1.59 to 3.39 0.41
Liver cirrhosis 0.11 –6.57 to 6.79 0.97
Cancer 0.99 –1.40 to 3.38 0.42
Immune compromised host –0.05 –2.42 to 2.32 0.97
Healthcare-associated acquisition 1.07 –0.53 to 2.68 0.19
Pitt bacteraemia score (per point) 1.55 1.15–1.96 <0.001
Inappropriate empirical antimicrobial
therapy
3.65 0.44–6.87 0.03
FQ-NS bloodstream isolate 2.28 0.21–4.35 0.03
Note: FQ-NS, ﬂuoroquinolone non-susceptible.
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with longer HLOS in patients who survived Gram-negative BSI
(Table 4).
Patients with BSI due to FQ-NS Gram-negative bacilli
received longer mean treatment duration with inpatient intra-
venous antibiotics compared with those with FQ-S blood-
stream isolates (9.1 versus 7.1 days, p 0.001). In addition,
patients with BSI due to FQ-NS organisms were nearly twice as
likely as those with BSI due to FQ-S bacteria to be discharged
from the hospital on intravenous antibiotics (15% versus 8%, p
0.05). This was probably inﬂuenced by lack of reliable oral
options for intravenous to oral switch therapy in patients with
BSI due to FQ-NS isolates (see Supplementary material,
Table S2).DiscussionTo our knowledge, this is the ﬁrst study to examine the asso-
ciation between FQ-NS and HLOS in patients with Gram-TABLE 4. Multivariate linear regression results for
independent risk factors of prolonged hospital length of stay
in survivors of Gram-negative bloodstream infection
Variable
Parameter
estimate
in days 95% CI p
Male gender 0.46 –1.12 to 2.04 0.57
Non-urinary source of infection 2.57 0.97–4.16 0.002
Pitt bacteraemia score (per point) 1.54 1.13–1.96 <0.001
Healthcare-associated acquisition –0.64 –2.19 to 0.92 0.42
Inappropriate empirical antimicrobial
therapy
3.65 0.43–6.86 0.03
FQ-NS bloodstream isolate 0.57 –1.53 to 2.67 0.60
Note: FQ-NS, ﬂuoroquinolone non-susceptible.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectnegative BSI. Although FQ-NS was not an independent risk
factor for HLOS, it was a marker for treatment with inappro-
priate empirical antimicrobial therapy, which was a predictor of
longer HLOS.
The association between inappropriate antimicrobial therapy
and HLOS stay has been previously described in patients with
Gram-negative sepsis [14,15]. In the current study, patients
who received inappropriate empirical antimicrobial therapy for
Gram-negative BSI spent an additional 3 days in the hospital
compared with those who received appropriate therapy. FQ-
NS bloodstream isolates, particularly FQ-NS E. coli, were
more likely to be resistant to other antimicrobial agents and be
multi-drug resistant than FQ-S isolates. Therefore, patients with
BSI due to FQ-NS organisms were more likely to receive
inappropriate empirical antimicrobial therapy, whether they
have received a ﬂuoroquinolone or other antimicrobial regi-
mens. In the current study, 7 of 90 patients (8%) with FQ-NS
bloodstream isolates received empirical therapy with ﬂuo-
roquinolones. Although the non-stratiﬁed use of ﬂuo-
roquinolones for empirical therapy of Gram-negative BSI has
been discouraged due to increasing antimicrobial resistance
rates [8,16], ﬂuoroquinolones remain one of few remaining
antimicrobial treatment options in patients with severe β-lac-
tam allergy [17].
The association between FQ-NS and inappropriate empirical
antimicrobial therapy has been demonstrated in hospitalized
patients with E. coli and Klebsiella pneumoniae infections [18].
The current study was not powered to detect a difference in
mortality between BSI due to FQ-S and FQ-NS Gram-negative
bacilli because this has been previously examined [18]. In
addition, the association between inappropriate empirical
antimicrobial therapy and mortality has been widely docu-
mented locally and elsewhere [5–7]. Development of institu-
tional guidelines for management of Gram-negative BSI may
improve the selection of empirical antimicrobial therapy and
hence outcomes [2,19].
The predominance of E. coli among FQ-NS bloodstream
isolates and the magnitude of antimicrobial resistance mecha-
nisms harboured by FQ-NS E. coli bloodstream isolates in the
current study are suggestive of the phenotypic pattern of E. coli
type ST131. Escherichia coli type ST131 is an emerging pathogen
that has been labelled as pandemic [20,21]. Future studies with
molecular testing to examine for E. coli type ST131 in the local
population could yield valuable results. Moreover, rapid iden-
tiﬁcation of FQ-NS bloodstream isolates using clinical risk
scores or molecular techniques such as PCR for E. coli type
ST131 may lead to improvement in the adequacy of empirical
antimicrobial therapy and clinical outcomes.
It is conceivable that higher acute severity of illness and non-
urinary source of BSI were independently associated withious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 843–849
CMI Brigmon et al. Fluoroquinolone-resistant bloodstream isolates 847longer HLOS. Both variables were previously demonstrated to
be predictors of mortality following Gram-negative BSI [22].
Patients with a high Pitt bacteraemia score may have delayed
clinical improvement. Similarly, patients with non-urinary
source of BSI may have deep-seated infections requiring inva-
sive procedures for source control, which may prolong re-
covery time and HLOS.
The current study demonstrated that the association be-
tween non-susceptibility to ﬂuoroquinolones and other classes
of antibiotics also limited deﬁnitive antimicrobial treatment
options. This was suggested by longer treatment duration with
inpatient intravenous antibiotics and increased use of intrave-
nous antibiotics outside the hospital in patients with FQ-NS
compared with those with FQ-S bloodstream isolates.
Although many FQ-NS bloodstream isolates remained suscep-
tible to third-generation cephalosporins, local healthcare
providers were reluctant to use oral third-generation cepha-
losporins for deﬁnitive therapy of BSI, probably because of the
low bioavailability of this class of antibiotics [23]. Future studies
to evaluate the effectiveness of oral antimicrobial regimens for
deﬁnitive therapy of Gram-negative BSI are desirable. More-
over, treatment of Gram-negative BSI with a total of 14 days of
antibiotics remains commonplace [19], despite some suggestion
to use shorter treatment courses for BSI due to a heteroge-
neous group of microorganisms, including coagulase-negative
staphylococci [24]. Future studies to examine the optimal
antibiotic treatment duration exclusively in patients with Gram-
negative BSI are also warranted.
There has been a concerning increase in ﬂuoroquinolone
resistance among Gram-negative bloodstream isolates over
the past two decades [8–10,25,26]. The 19% FQ-NS rate
among bloodstream isolates in the current study is consistent
with the results of the most recent population-based studies
in North America [9,10]. The increase in ﬂuoroquinolone
resistance rates poses a public health concern from the cost
of medical care standpoint. It appears that FQ-NS directly and
indirectly contributes to the increasing need for treatment
with outpatient intravenous antibiotics and longer HLOS in
patients with Gram-negative BSI, respectively. The two
additional days of hospitalization in patients with FQ-NS
compared with FQ-S Gram-negative BSI, which is mostly
due to receipt of inappropriate empirical antimicrobial ther-
apy, costs the healthcare system an additional $8500 on
average (International Federation of Health Plans 2012
Comparative Price Report. Accessed 19 January 2014) http://
www.ifhp.com. The additional cost of peripherally inserted
central venous catheters and intravenous antibiotics following
hospital discharge in patients with FQ-NS Gram-negative BSI,
which is probably due to lack of reliable oral options, andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologypotential complications associated with that therapy, further
stretches the healthcare system. This emphasizes the need for
antimicrobial stewardship to prevent a further increase in
antimicrobial resistance rates and hence excessive burden of
healthcare cost [27].
Since previous exposure to ﬂuoroquinolones has been
identiﬁed as a risk factor for development of ﬂuoroquinolone
resistance [17,28], an effective strategy would be to minimize
unnecessary use of ﬂuoroquinolones for minor indications.
Antimicrobial stewardship programs have been successful in
reducing unnecessary use of antimicrobial agents, including
ﬂuoroquinolones, in acute care hospitals [29]. In fact, ﬂuo-
roquinolone resistance rates among Gram-negative bacilli are
lower among hospital-acquired compared with community-
acquired isolates in some geographical areas in the USA [17].
This emphasizes the need for antimicrobial stewardship in the
community. Education of community prescribers on the
proper use of antimicrobial agents and discouraging ﬂuo-
roquinolone use for upper respiratory tract and other minor
infections may reduce ﬂuoroquinolone resistance rates. In
addition, use of ﬂuoroquinolones as ﬁrst-line agents for un-
complicated cystitis should be discouraged as ﬂuoroquinolones
should be reserved for more serious upper urinary tract
and deﬁnitive therapy for Gram-negative BSI [19,30]. Since
long-term care facilities appear to be a reservoir for
ﬂuoroquinolone-resistant isolates, expansion of antimicrobial
stewardship programmes to include such facilities may be
beneﬁcial. Limiting the use of ﬂuoroquinolones to patients with
true infections rather than asymptomatic bacteriuria may
reduce the magnitude of resistance in long-term care facilities.
In addition, increasing public awareness about risks and ben-
eﬁts of antimicrobial agents is equally important as that would
reduce pressure on healthcare professionals to provide un-
necessary antibiotic prescriptions.
The study has limitations. First, despite adjustments for the
most relevant underlying medical conditions for Gram-negative
BSI [22], it remains possible that other co-morbidities could
impact HLOS. Exclusion of nosocomial BSI from the study
probably minimized such an effect. Second, source control
remains an essential component for successful treatment of
Gram-negative BSI. Adjustments for appropriate source control
are difﬁcult in a retrospective cohort design. Finally, the study
was conducted in one geographical setting. Studies from
different geographical locations may provide more generalizable
views.
In summary, antimicrobial resistance continues to stretch
healthcare resources. There is an urgent need for new strate-
gies in reducing the global impact of ﬂuoroquinolone resistance
on the healthcare system.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 843–849
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